Atricure Inc. Stock
Price
Target price
€28.80
€28.80
-3.360%
-1.0
-3.360%
€43.22
23.07.26 / Frankfurt
WKN: A0ES9W / Symbol: ATRC / Name: AtriCure / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Atricure Inc. Stock
Heavy losses for Atricure Inc. today as the stock fell by -€1.000 (-3.360%).
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Atricure Inc..
As a result the target price of 43 € shows a positive potential of 49.31% compared to the current price of 28.8 € for Atricure Inc..
Pros and Cons of Atricure Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | -3.360% | -2.703% | 18.033% | -53.548% | -15.294% | -53.548% | -57.647% |
| Lantheus Holdings Inc | -0.980% | -0.762% | -2.146% | 46.482% | 59.441% | 15.913% | - |
| Natera Inc | 1.170% | -1.314% | 12.845% | 97.288% | 18.173% | 443.925% | 143.770% |
| IRadimed Corp | -1.180% | 4.294% | 5.590% | 76.349% | 2.410% | - | - |
Comments
AtriCure (ATRC) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (ATRC) was upgraded by Freedom Capital to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (NASDAQ:ATRC) was given a new $55.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
News
AtriCure Q2 Earnings Call Highlights
Key Points
- Interested in AtriCure, Inc.? Here are five stocks we like better.
- AtriCure posted strong Q2 2026 results, with revenue up 12.8% to $153.6 million and a return to GAAP
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
This medical device innovator for cardiac surgery reported an insider sale amid a year of negative total returns.
Doraiswamy Vinayak, Chief Scientific Officer of AtriCure (NASDAQ:ATRC), reported the
